A Message to cardiologists
As a cardiologist treating patients who have had a heart attack, you are aware of the potential medical benefits of regenerating myocardium following a heart attack.
The ALLSTAR (ALLogeneic Heart STem Cells to Achieve Myocardial Regeneration) Phase II clinical trial is designed to investigate the ability of cardiac cell therapy to regenerate heart muscle and decrease scar tissue to prevent or attenuate the development of heart failure. In ALLSTAR, the cardiac cell therapy is infused via a coronary catheter in a simple procedure in a standard interventional suite.
As the referring physician, the ALLSTAR trial doctor will provide you with the results of important trial-related tests, procedures and assessments. These will aid you in providing care to your patient.
We encourage you to read more about the ALLSTAR trial. We welcome your phone call and participation in this research study. Learn more about the trial.